Φορτώνει......
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients
CONTEXT: Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in T2DM and obesity. The interplay between ambient fatty acids (FFA) and GLP-1, remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (aka HCA(2) and GPR109a) receptor. OBJECTIVE...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Clin Endocrinol Metab |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212086/ https://ncbi.nlm.nih.gov/pubmed/30726969 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02503 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|